eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
6/2007
vol. 45
 
Share:
Share:
more
 
 
abstract:

Review paper
Subcutaneous methotrexate injection in the treatment of rheumatoid arthritis

Jerzy Świerkot

Reumatologia 2007; 45, 6: 407–414
Online publish date: 2007/12/20
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Methotrexate (MTX) is the most frequently used drug in the treatment of rheumatoid arthritis. Oral administration has long been the standard way of administration. Generally it is well tolerated adverse some side effects (gastrointestinal) may lead to discontinuation of therapy. A significant lower bioavailability could be observed when MTX was administered orally while the bioavailability after subcutaneous application was similar to the intramuscular treatment. In some patients who did not tolerate or showed no significant clinical improvement under oral MTX, suppression of disease activity could be seen after switching to subcutaneous MTX. The subcutaneous injection is the only parenteral form which can easily be administered at home.
keywords:

methotrexate, rheumatoid arthritis



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe